In a building nearly 80 years old tucked on the campus of Hartford Hospital in Hartford, Connecticut, the biotechnology company Genomas has a surprising amount of wall space dedicated to art. In one corner, the startling whiteness is interrupted by *Gene Collage \#1*, in which microarray data has been transformed into a modernist-style collection of colorized squares. Removed from this impromptu gallery space, the walls resume their institutional flavor, and a pair of large doors open to reveal a lab performing state-of-the-art science. It is here that the red, white, and black landscape of the artwork is fully realized in nanotechnological bliss: Gene chips, each the size of a stick of gum and containing one million single nucleotide polymorphisms or SNPs, rest on the lab bench. Using these DNA microarrays and other recent advances in genomics, the aptly named Genomas aims to usher in the era of personalized medicine with its trademark PhysioTypes.

Genomas was founded four years ago by President and CEO Gualberto Ruaño, MD PhD, whose vision for the company is to use DNA-guided technology to help physicians avoid dangerous and unnecessary side effects of drugs for patients on an individual basis. Ruaño is a veteran of the biotechnology sector; Genomas is his third biotech company and is consistent with his lifelong interest in polymorphisms. As a graduate student at Yale University, he developed a patent for the rapid sequencing of polymorphisms that became the basis of his first company, BIOS Laboratories, and TruGene®, an FDA-approved HIV management tool currently in worldwide use. Ruaño then became interested in pharmacogenetics, the sub-discipline of pharmacology dealing with the effect of genetic factors on drug reactions. In 1997, Ruaño formed Genaissance and created a platform technology that would extend beyond cytochromes, the best known drug metabolizing enzymes. At Genaissance, Ruaño says genes were viewed as "haplotypes as opposed to single polymorphisms," and pharmaceutical partners could embed this technology in their clinical trials. While testing drugs for efficacy and safety, researchers also would evaluate genetic variability and determine if genetic components could, in part, explain side effects or protection. Although successful, Ruaño lamented his technology "remained used in pharmaceutical R&D and didn't go to patient care." Determined to focus on patients, Ruaño decided to found Genomas, this time is using *physiogenomic* tools to directly affect the way doctors prescribe medicine.

"The model here is to work with clinicians identifying areas of medical need where the medications are not working the way they are supposed to for some people. It's not about a lesson on genetic heterogeneity or linkage disequilibrium; it really is to guide treatment decisions," he says.

Working in partnership with Hartford Hospital --- which provided the company its seed investment --- Genomas actively is collecting select patients' clinical information and DNA to translate this data into medical devices called PhysioTypes. The first step in this process involves scanning the total genome of patients taking a particular drug. A proprietary algorithm can then identify prevalent polymorphisms. Ruaño explains: "We create basically a distribution of cases, and genetically we co-relate the clinical responses with genetic differences. The genetic differences are encoded by a series of polymorphisms, which have a high frequency in people who develop the side effect or vice-versa; there are some polymorphisms that actually have a higher frequency in the people who did not develop side effects --- so it's not just risk, it's also protection."

Ultimately, new patients can have their DNA evaluated for the identified markers and be placed on a spectrum of risk that can be provided to physicians "in a way that is actionable." For instance, if a statin patient ranks in the 90th percentile of risk for Lipitor® but only the 20th percentile for Zocor®, the physician can avoid the common practice of prescribing medication by trial and error and start the patient directly on Zocor®. Even if the genomic profiling fails to reveal a preferred medication, it can alert both patient and doctor to the heightened risk, allowing for alternative interventions and optimal management of the potential side effects.

The PhysioType results, however, are still predictions. The success rate of the PhysioType in detecting risk for patients who would go on and develop side effects is approximately 85 percent, while the accuracy of those predicted not to have side effects is 90 percent. The PhysioType result is not definitive, and even if it were widely used there would still be a significant number of patients who would have to try several drugs before they found their best match. Nevertheless, the predictive power of the PhysioType is an improvement on current methods and could mean safer and less time-consuming prescribing routines for a majority of patients.

Although Genomas' DNA-guided approach is theoretically applicable to any patient, Ruaño initially is "working on making sure that the specific niches where we establish this technology are absolutely compelling." With funding from the National Institutes of Health and the support of Hartford Hospital, Genomas is developing PhysioTypes for two core groups of medications notorious for affecting a considerable percentage of their users with serious side effects: atypical antipsychotics and statins. The atypical antipsychotics prescribed to treat schizophrenia and bipolar disorder often result in significant weight gain and metabolic dysfunction leading to diabetes. Similarly, some individuals using high doses of statins to lower cholesterol and/or mitigate cardiovascular disease develop neuromuscular side effects.

In 2006, in cooperation with the Joslin Diabetes Center Affiliate at New Britain General Hospital, Genomas expanded to include diabetics managing their disease with insulin sensitizers such as Actos® and Avandia®. Since these thiazolidinediones are transcription factor agonists, they are prone to exert multiple effects --- in particular, edema and heart failure --- and are thus good candidates for physiotyping.

In addition to increasing the number of specific markets, PhysioTypes will have to be continually updated each time a new drug is approved by the FDA in order to include the new drug in treatment options being evaluated for adverse effects. Ruaño views this as an advantage because the PhysioType "learns from this clinical experience" and likens the system to software versions "where the next version has more precision in regard to the first version." Ruaño adds that because the PhysioTypes are combinatorial, each new drug will need only about 200 patients, which will greatly speed the learning curve. This remarkably small number of samples is possible because the side effects are incredibly prevalent, afflicting about 20 percent of users. A two-fold drop in prevalence would mean twice as many patient samples are needed to create the PhysioType.

Accordingly, Ruaño is most interested in side effects considered clinically intensive, as opposed to the rarer and often lethal adverse drug reactions (ADRs) such as those that originally forced Vioxx off the market in 2004. If certain reactions only occur in 1 in 5,000 or 10,000 patients, the PhysioTypes will not necessarily incorporate this information into the system. Ruaño believes, however, there is a "connection between the catastrophic events and the more clinically intensive events and those have to do with common mechanisms that underlie them both." Indeed, all of the drugs Genomas is examining are accompanied by warning labels --- some with black box warnings --- or have been withdrawn from the market due to safety concerns. It is possible Genomas' technology could prevent certain drugs from being withdrawn by limiting access to those at risk, and it has important implications for the pharmaceutical industry.

Beyond the concomitant identification of the ADRs, the clinically intensive side effects themselves are often disabling and remain a serious concern. Ruaño says these side effects are a strain on both patients and the healthcare system and describes an all-too-common situation in which a patient who came to a physician for treatment for one disease returns with complaints engendered by the necessary medication.

"Now you have other things to worry about and diagnose and treat, and so that triggers a series of medical transactions where the patient has to keep coming back ... It's the last thing you want," he says.

If PhysioTypes are capable of eliminating even a fraction of these adverse reactions, not only will individual patient care improve, but the burden on the already encumbered healthcare system also will be attenuated.

In fact, it is the healthcare system that may determine the trajectory of the PhysioType and the nascence of personalized medicine. Ruaño knows the success of his platform will depend on its clinical utility within the system. Practically and economically, how will this innovation become integrated into the healthcare system? For now, Ruaño's answer is triage. Citing laparoscopy and medical imaging, Ruaño explains that innovations in medicine have a history of being triaged, and he believes DNA-guided medicine will be no different.

"When \[laparoscopy\] initially started back in the 1970s --- that was revolutionary. That you would use video and robotics to operate on people --- that was really wild at the time. And now, 30 years later, you wouldn't even think twice about it."

Thus, Ruaño believes that introducing this technology into select markets will ease the medical community toward more ubiquitous use of PhysioTypes, although it will likely be another decade until there is a "more profound change of how we practice medicine."

Whether or not PhysioTypes are the harbingers of universal DNA-guided medicine, questions abound about the proper use and protection of an individual's genetic code in 21st century healthcare. According to Ruaño, the full-fledged use of genomics in medicine is neither ethically conscionable nor sustainable until the healthcare system is based on prevention and "when you can say that because these genetic factors are partial contributors to disease, you can do x, y, and z to override that, in terms of lifestyle." Ruaño believes the ethical risk of his PhysioTypes is relatively low because they do not involve an entire genome scan and the DNA is not stored. Instead, the sample is evaluated for approximately 40 markers, which can advise an optimal regimen, and the DNA is thrown away. "We limit the risk by measuring selected genes, and we optimize the value so that you have a good risk-to-reward ratio. That's how we operate," he says. The development of the PhysioTypes does involve whole genome scans, but these are for research purposes only. Nevertheless, Ruaño is cognizant of the concerns individuals have about volunteering their DNA and advises: "Do what you need to do for the problem, no more, and make sure the value justifies the risk."

While the main goal of Genomas is to improve clinical care, there is also the potential to discover the mechanism of action (and bystander dysfunction) of certain drugs. Ruaño says, "We learn a lot of new information about how these drugs work ... so from a scientific perspective already there is knowledge that has been gathered." For example, in a study published in *Molecular Psychiatry* last year, Ruaño and colleagues reported that two antipsychotics may induce pre-diabetic symptoms by two separate mechanisms \[[@R1]\]. The DNA of patients on olanzapine and risperidone was screened for 13 candidate genes and 29 SNPs, and, like a PhysioType, this information was integrated with the weight profiles of each patient. Interestingly, patients with weight gain on olanzapine had higher frequencies of SNPs in genes involved in peripheral lipid homeostasis, while those on risperidone had higher frequencies of genes involved in brain appetite peptide regulation. A similar approach also was used to find a correlation between the myalgia pain of statin patients and two SNPs in serotonin receptors, as published in a 2007 issue of *Muscle & Nerve* \[[@R2]\]. While the number of patients in the study experiencing myalgia was small and the research does not prove causality, the concept that serotonin receptor function is involved in modulating pain is an intriguing starting point for further investigation. For Ruaño, the ability to conduct this kind of research is at the core of Genomas. "Our big paradigm change is that we learn from clinical variability. We're learning from patient care, and we're translating that into mechanism," he says.

The bi-directional flow of information is part of what makes Genomas so revolutionary and is captured with a stroll through the halls --- from gallery to lab and back. The minimalist, solid blocks of color of *Gene Collage \#1* are infinitely more beautiful knowing they represent the potential for a new age of medicine in which drugs work precisely as intended.
